Sanofi India stock: Q3 profit rises 54% as dividend declared
Published on 11/06/2026 at 02:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points for investors
- Sanofi India reported stronger Q3 profitability, supported by its diabetes and public-sector businesses.
- The board declared an interim dividend and set November 5, 2026, as the record date.
- Export sales grew at a double-digit rate, while strategic partnership revenue remained broadly stable.
Sanofi India reported a sharp rise in third-quarter profit and declared an interim dividend, according to CNBC TV18. The results relate to the quarter ended September 30, 2026, and were published on October 29, 2026.
Profit for the period rose 53.6 percent year on year to 117 crore INR from 76 crore INR. Revenue from operations increased 3.43 percent to 491.70 crore INR, while EBITDA grew 20.1 percent to 161 crore INR. The EBITDA margin widened to 32.8 percent from 28.2 percent.
Diabetes portfolio supports growth
Sanofi India said domestic net sales increased 2 percent and total net sales rose 4 percent from a year earlier. Its insulin portfolio grew 9 percent, with Lantus, Toujeo, Apidra and Soliqua contributing to performance.
The company said its diabetes injectable portfolio held a 55 percent market share. Its public-sector business expanded 85 percent, driven by new accounts in innovative analogue segments, while export sales recorded double-digit growth. Revenue from strategic partnerships in cardiovascular, oral anti-diabetes and central nervous system therapies remained broadly stable.
Dividend sets next shareholder date
Sanofi India's board declared an interim dividend of 75 INR per equity share with a face value of 10 INR. November 5, 2026, was set as the record date for determining eligible shareholders.
Sanofi India at a glance
- Company: Sanofi India Limited
- ISIN: INE058A01010
- Reporting period: Third quarter 2026, ended September 30, 2026
- Profit for the period: 117 crore INR
- Revenue from operations: 491.70 crore INR
- Interim dividend: 75 INR per share
- Record date: November 5, 2026
Sanofi India is an India-based pharmaceutical business offering vaccines and therapies for diabetes, rare diseases and transplant needs, according to Sanofi India. The company is part of Sanofi, an R&D-driven biopharmaceutical group operating across medicines and vaccines in international markets.
The BSE Sensex provides the broader Indian market backdrop for investors: BSE Sensex market coverage.
